Dermata Rises 5% In Pre-market Upon Positive Phase 1b Trial Results For Psoriasis Drug

Shares of California-based Dermata Therapeutics, Inc. (DRMA), are up more than 5 percent in pre-market after it announced positive topline results from phase 1b clinical trial of DMT310, its lead product candidate for the treatment of mild-to-moderate Psoriasis.

Dermata is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions.

DMT310 is a multifactorial, naturally derived product from a unique freshwater sponge that is harvested under specific environmental conditions and then processed into a powder using the proprietary, multifaceted, Spongilla technology. The powder is mixed with a fluidizing agent immediately prior to application.

DMT310's organic components contain chemical compounds that when tested in vitro, have shown a dose dependent inhibition of both IL-17A and IL-17F, which are believed to be major effector cytokines in the pathogenesis of psoriasis.

DMT310, with both mechanical and chemical mechanisms of action, is currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.

The results of the single-arm Phase 1b study revealed safety and tolerability as well as demonstrated efficacy improvements in PGA, PASI, and pruritis scores for the target psoriatic lesion.

DRMA has traded between $3.94 and $6.50 in the past 52 weeks. It is currently trading in pre-market at $4.66, up $0.26 or 5.91 percent from previous close.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT